Exclusive Online Content
Symeres Acquires Organix, Adding Lipids Expertise & Strategic Foothold in the US
Symeres recently announced the acquisition of Organix Inc., a US-based specialized organic chemistry services provider with a focus on lipids…..
SOTIO Initiates CLAUDIO-01 Trial With Antibody-Drug Conjugate SOT102 in Patients With Gastric & Pancreatic Cancer
SOTIO Biotech recently announced it has dosed the first patient in its Phase 1/2 CLAUDIO-01 trial of SOT102 in patients with gastric and pancreatic cancer. SOT102 is the lead program of….
First European Union Patient Dosed With 177Lu-PNT2002 in the Phase 3 SPLASH Trial
POINT Biopharma Global Inc. recently announced the first patient in the European Union (EU) has been dosed in the Phase 3 SPLASH trial (NCT04647526). The SPLASH trial….
Taconic Biosciences & Biomodels Establish Microbiome Initiative
Taconic Biosciences and Biomodels have recently launched the Taconic-Biomodels Microbiome Initiative (TBMI), providing investigators with seamless access to complete germ-free and gnotobiotic microbiome study solutions, from design to data….
Sol-Gel Technologies & Galderma Announce FDA Approves First Topical Rosacea Treatment With Microencapsulated BPO
Sol-Gel Technologies, Ltd. recently announced the Food and Drug Administration (FDA) approval of its drug product, EPSOLAY, a proprietary cream formulation of….
Blacktrace Launches Particle Works – The New Dedicated Particle Engineering Brand
Particle Works’ game-changing particle engineering platforms are set to revolutionize the way customers discover, develop and scale-up particle production for a wide range of….
Catalent to Invest $350 Million in Integrated Biologics Drug Substance & Drug Product Manufacturing
Catalent recently announced a multi-year $350-million investment at its facility in Bloomington, IN, to expand biologics drug substance and drug product manufacturing….
Brooklyn ImmunoTherapeutics Announces Establishment of New R&D Facility for Advancement of Engineered Cellular Medicines
Brooklyn ImmunoTherapeutics, Inc. recently announced the establishment of a new corporate and research and development facility at The Boardwalk at Science Center Drive in San Diego, CA, to support translational….
Cocrystal Pharma Collaborates With the NIAD to Evaluate COVID-19 Protease Inhibitors
Cocrystal Pharma, Inc. recently announced a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID) for exploratory preclinical studies to….
ProMed Pharma Announces Preclinical Rat Study to Assess Pharmacokinetics of Novel Long-Acting Contraceptive Implant
ProMed Pharma recently announce the initiation of preclinical evaluation of a novel fully resorbable contraceptive implant. The implant, developed in a project funded by the Bill & Melinda….
Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study for the Treatment of Osteogenesis Imperfecta
Ultragenyx Pharmaceutical Inc. recently announced the first patient has been dosed in a clinical study for the treatment of Osteogenesis Imperfecta (OI) in patients….
BioXcel Therapeutics Announces Formation of OnkosXcel Therapeutics to Develop Medicines Focused in Oncology
BioXcel Therapeutics, Inc. recently announced the formation of wholly owned subsidiary OnkosXcel Therapeutics, Inc. to develop transformative medicines in….
NEC & Shionogi Enter Strategic Research Collaboration for Novel Hepatitis B Therapeutic Vaccine
NEC Corporation and Shionogi & Co., Ltd. recently announced the execution of a strategic research collaboration agreement for the development of a novel hepatitis B therapeutic….
Ocugen to Commercialize COVAXIN in Mexico, Rights Now Encompassing All of North America
Ocugen, Inc. and Bharat Biotech recently announced they have entered into an amendment to their Co-development, Supply and Commercialization Agreement to expand Ocugen’s exclusive….
Halozyme to Acquire Antares Pharma to Create a Specialty Product & Drug Delivery Leader
Halozyme Therapeutics, Inc. and Antares Pharma, Inc. recently announced the companies have entered into a definitive agreement pursuant to which Halozyme will acquire Antares for….
Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 Clinical Trial for Multiple Sclerosis
Imcyse recently announced the first patient has been dosed in the adaptive Phase 1/2 clinical trial evaluating Imotope IMCY-0141 in patients with relapsing-remitting multiple sclerosis….
Venomtech Announces New Drug Development Collaboration With Charles River
Venomtech is collaborating with Charles River Laboratories, International Inc. to help drug developers explore venom-derived compounds for a wide range of….
Matinas BioPharma & BioNTech Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines
Matinas BioPharma and BioNTech SE recently announced they have entered into an exclusive research collaboration to evaluate the combination of mRNA formats and….
Eton Pharmaceuticals Announces FDA Approval of Cysteine Hydrochloride Injection
Eton Pharmaceuticals, Inc. recently announced it has received final approval from the US FDA for its cysteine hydrochloride abbreviated new drug application (ANDA), a bioequivalent generic of….
FREEZE-DRYING MICROSCOPY - Unravelling the Complexities of Freeze-Drying Pharmaceuticals With Advanced Microscopy Techniques
Paul Matejtschuk, PhD, Prof Yvonne Perrie, and Robert Gurney, PhD, say FDM is being used to analyze the most challenging formulations that require sophisticated stabilization methods. By altering and adapting the three main freeze-drying stages to specific formulations, researchers are providing the tools needed for the pharma industry to improve its drug development processes and maintain drug stability when scaling up to production.
